Pavaki Capital Management’s Roivant Sciences ROIV Stock Holding History

Pavaki Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-40,000	Closed	-$868K	–	160
2025 Q4	$868K	Buy	+40,000	New	+$789K	0.34%	46

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pavaki Capital Management's ROIV Position: Q1 2026 in Review

Pavaki Capital Management sold out of Roivant Sciences (ROIV) in Q1 2026, closing a stake of 40,000 shares — an estimated $868K sold.

Pavaki Capital Management first reported a position in ROIV in Q4 2025 and held it in 1 quarter. The position peaked at $868K in Q4 2025. 442 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

Pavaki Capital Management reported no remaining Roivant Sciences position as of Q1 2026 after selling out during the quarter.
Pavaki Capital Management sold 40,000 Roivant Sciences shares in Q1 2026, an estimated $868K.
Pavaki Capital Management first reported a position in Roivant Sciences in Q4 2025 and held it in 1 quarter.
Pavaki Capital Management's Roivant Sciences position peaked at $868K in Q4 2025.
442 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Pavaki Capital Management's 13F filing for Q1 2026, filed 7 Aug 2026.